These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

608 related articles for article (PubMed ID: 10210217)

  • 1. Bone pain palliation with 85Sr therapy.
    Giammarile F; Mognetti T; Blondet C; Desuzinges C; Chauvot P
    J Nucl Med; 1999 Apr; 40(4):585-90. PubMed ID: 10210217
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone pain palliation with strontium-89 in cancer patients with bone metastases.
    Giammarile F; Mognetti T; Resche I
    Q J Nucl Med; 2001 Mar; 45(1):78-83. PubMed ID: 11456379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relative efficacy of 32P and 89Sr in palliation in skeletal metastases.
    Nair N
    J Nucl Med; 1999 Feb; 40(2):256-61. PubMed ID: 10025832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose estimation in strontium-89 radiotherapy of metastatic prostatic carcinoma.
    Breen SL; Powe JE; Porter AT
    J Nucl Med; 1992 Jul; 33(7):1316-23. PubMed ID: 1613572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of low-dose cisplatin on 89Sr therapy for painful bone metastases from prostate cancer: a randomized clinical trial.
    Sciuto R; Festa A; Rea S; Pasqualoni R; Bergomi S; Petrilli G; Maini CL
    J Nucl Med; 2002 Jan; 43(1):79-86. PubMed ID: 11801708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Strontium-89: a desirable therapeutic for bone metastases of prostate cancer].
    Ma YB; Yan WL; Dai JC; Xu F; Yuan Q; Shi HH
    Zhonghua Nan Ke Xue; 2008 Sep; 14(9):819-22. PubMed ID: 18998467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical experience with strontium-89 in prostatic and breast cancer patients.
    Robinson RG; Preston DF; Baxter KG; Dusing RW; Spicer JA
    Semin Oncol; 1993 Jun; 20(3 Suppl 2):44-8. PubMed ID: 8503027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitation of biochemical markers of bone resorption following strontium-89-chloride therapy for metastatic prostatic carcinoma.
    Papatheofanis FJ
    J Nucl Med; 1997 Aug; 38(8):1175-9. PubMed ID: 9255144
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decreased serum E-selectin concentration after 89Sr-chloride therapy for metastatic prostate cancer bone pain.
    Papatheofanis FJ
    J Nucl Med; 2000 Jun; 41(6):1021-4. PubMed ID: 10855628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of strontium-89 in endocrine-refractory prostate cancer metastatic to bone. Provincial Genitourinary Cancer Disease Site Group.
    Brundage MD; Crook JM; Lukka H
    Cancer Prev Control; 1998 Apr; 2(2):79-87. PubMed ID: 9765768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The efficacy of therapy using 89Sr-strontium chloride in 200 patients with bone metastases of a prostatic cancer].
    Haesner M; Buchali K; Pink V; Lips H
    Nuklearmedizin; 1992 Mar; 31(2):48-52. PubMed ID: 1373485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 186Re-etidronate in breast cancer patients with metastatic bone pain.
    Han SH; Zonneberg BA; de Klerk JM; Quirijnen JM; van het Schip AD; van Dijk A; Blijham GH; van Rijk PP
    J Nucl Med; 1999 Apr; 40(4):639-42. PubMed ID: 10210223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined therapy of Sr-89 and zoledronic acid in patients with painful bone metastases.
    Storto G; Klain M; Paone G; Liuzzi R; Molino L; Marinelli A; Soricelli A; Pace L; Salvatore M
    Bone; 2006 Jul; 39(1):35-41. PubMed ID: 16434248
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dosimetry of 188Re-hydroxyethylidene diphosphonate in human prostate cancer skeletal metastases.
    Liepe K; Hliscs R; Kropp J; Runge R; Knapp FF; Franke WG
    J Nucl Med; 2003 Jun; 44(6):953-60. PubMed ID: 12791825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Strontium-89 therapy for the pain of osseous metastases.
    Silberstein EB; Williams C
    J Nucl Med; 1985 Apr; 26(4):345-8. PubMed ID: 3920361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Strontium 89 therapy for the palliation of pain due to osseous metastases.
    Robinson RG; Preston DF; Schiefelbein M; Baxter KG
    JAMA; 1995 Aug; 274(5):420-4. PubMed ID: 7542352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [186Re]HEDP in the palliation of painful bone metastases from cancers other than prostate and breast.
    Minutoli F; Herberg A; Spadaro P; Restifo Pecorella G; Baldari S; Aricò D; Altavilla G; Baldari S
    Q J Nucl Med Mol Imaging; 2006 Dec; 50(4):355-62. PubMed ID: 17043634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 85Sr contaminant as a reliable tracer of 89Sr for monitoring urinary radioactivity in patients treated with 89Sr for bone metastases.
    De Agostini A; Mascaro L; Pizzocaro C; Panarotto MB; Bestagno M
    J Nucl Biol Med (1991); 1993 Mar; 37(1):38-44. PubMed ID: 7687149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic radionuclide therapy in pain palliation.
    Liepe K; Runge R; Kotzerke J
    Am J Hosp Palliat Care; 2005; 22(6):457-64. PubMed ID: 16323716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radionuclide therapy for painful bone metastases. An Italian multicentre observational study. Writing Committee of an Ad Hoc Study Group.
    Piffanelli A; Dafermou A; Giganti M; Colamussi P; Pizzocaro C; Bestagno M;
    Q J Nucl Med; 2001 Mar; 45(1):100-7. PubMed ID: 11456368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.